After Two Jury Verdicts, Court Finds Repatha Patents Invalid
Executive Summary
Delaware district court rules patent claims for antibodies targeting PCSK9 are invalid for lack of enablement; saga to continue with Amgen appeal.
You may also be interested in...
Regeneron's Evkeeza Approved For Ultra-Rare Genetic High Cholesterol – And Priced To Match
Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.
Vascepa Included In European Dyslipidemia Guidelines Ahead Of Approval
Amarin won't seek approval in the EU until later this year, but doctors there are encouraged to consider Vascepa for patients with high triglycerides despite statin therapy. Also, PCSK9 inhibitor guidelines were solidified for very high risk patients.
In A Win For Amgen, Court Blocks Sanofi/Regeneron's Praluent Sales In Germany
A court in Dusseldorf ruled that Praluent infringes a patent for Amgen's better-selling PCSK9 inhibitor Repatha, saying that Sanofi and Regeneron must stop selling their biologic in Germany. It's unclear whether there will be any readthrough to ongoing patent disputes in other countries.